Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations
Endocrine-Related Cancer · 01.06.2025 · 32 (6)
DOI: 10.1530/erc-25-0087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 27.05.2025. Verfasst von Jelka Kuiper und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Proto-Oncogene Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Homozygous pathogenic glucagon receptor gene (GCGR) mutations cause a syndrome with pancreatic glucagon cell hyperplasia and neoplasia (GCHN) and hyperglucagonaemia without a glucagonoma syndrome named Mahvash disease. The disease follows an autosomal recessive course and is an exceptionally rare hereditary pancreatic neuroendocrine tumour (panNET) syndrome, with only seven cases documented in the literature. The study aims to elucidate the genotype–phenotype correlation in Mahvash disease and panNET development. Clinical features, molecular profile, pancreatic pathology, and follow-up were studied in detail in six of the 11 family members. The patients’ medical records were reviewed up until November 2024. Eight family members were positive for the likely pathogenic GCGR c.455C>T (p.Ser152Phe) germline variant. Three of the family members were homozygous for the GCGR germline variant. Two homozygous patients showed GCHN in pancreatic resection samples, with one exhibiting lymphogenic and hepatic metastases. Three patients had a glucagon-positive tumour with distinct somatic mutations in the MEN1 gene. One family member, heterozygous for the GCGR variant, presented with three small panNET, with the one biopsied lesion showing glucagon immunoreactivity. We report the first study of a single family with multiple members presenting with GCNH caused by a novel germline GCGR variant. We are also presenting the first patient with liver metastases in GCHN and another patient with multiple small panNET heterozygous for the novel GCGR gene variant. Our observations highlight the malignant potential for GCHN and suggest that somatic MEN1 mutations may play a role in the development of glucagon-positive panNET from glucagon cell hyperplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Jelka Kuiper, Wouter W de Herder, Johannes Hofland
Zitieren
APA
Kuiper, J., de Herder, W. W., Ben Brahim, Y., van Velthuysen, M. F., Brosens, L. A. A., Feelders, R. A., Langendonk, J. G., van Marion, R., Korpershoek, E., Klöppel, G., Wagner, A., & Hofland, J. (2025). Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations. Endocrine-Related Cancer, 32(6). https://doi.org/10.1530/erc-25-0087
Vancouver
Kuiper J, de Herder WW, Ben Brahim Y, van Velthuysen MF, Brosens LAA, Feelders RA, et al. Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations. Endocrine-Related Cancer. 2025;32(6). doi:10.1530/erc-25-0087
BibTeX
@article{Kuiper2025,
author = {Kuiper, Jelka and de Herder, Wouter W and Ben Brahim, Yassine and van Velthuysen, Marie-Louise F and Brosens, Lodewijk A A and Feelders, Richard A and Langendonk, Janneke G and van Marion, Ronald and Korpershoek, Esther and Klöppel, Günter and Wagner, Anja and Hofland, Johannes},
title = {Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations},
journal = {Endocrine-Related Cancer},
year = {2025},
volume = {32},
number = {6},
doi = {10.1530/erc-25-0087}
}
EUVIMED